Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
Article in Haemophilia (October 2020)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
Article in Haemophilia (October 2020)
Article in Blood Coagulation & Fibrinolysis (April 2020)
Article in BioDrugs (October 2019)